Your cart is empty
Your cart is currently empty. Let us assist you in finding the right product.
Uro Oncology
LHRH 22.5
LHRH 22.5 is a long-acting leuprolide acetate depot, supplied as a 3-month intramuscular injection. The house describes rapid and sustained testosterone suppression, a median PSA decline above 90% within 23 months, and a lower risk of cardiotoxicity than surgical orchidectomy.
MRP ₹16,950
- Form Depot injection
- Pack One combipack, 22.5 mg/vial
- Dose 22.5 mg intramuscular depot, as a 3-month injection. For single use, as directed by the physician.
- Leuprolide acetate depot injection 22.5 mg
- Management of advanced prostate cancer in men
- Rapid and sustained testosterone suppression
- An alternative to the physical and psychological burden of orchidectomy
LHRH 22.5 is the only brand in uro-oncology, and the lane is short because the list is short. It is a long-acting leuprolide acetate depot, 22.5 mg in one combipack, for a 3-month intramuscular injection, single use, as directed by the physician. The MRP is ₹16,950. The indications are management of advanced prostate cancer in men, rapid and sustained testosterone suppression, and an alternative to the physical and psychological burden of orchidectomy. The house describes rapid and sustained testosterone suppression, a median PSA decline above 90 percent within 23 months, and a lower risk of cardiotoxicity than surgical orchidectomy. Those three descriptions stay in the house’s voice. This page does not add survival language the house did not use, and it does not soften orchidectomy into a slogan.
There is no sister strength. A sidebar that offered “other oncology options” would be inventing a range. The honest sidebar says this is the lane, and then it offers the journal and the office. Advanced prostate cancer in men is the population on the indication. It is not a general hormone product, and it is not an andrology capsule. GO DADY’s cardiac and fertility support has no business in the same sentence as a depot injection except to warn a hurried buyer that the catalogue contains both a ₹695 capsule and a ₹16,950 vial. They are not a protocol. They are two doors.
The 90 percent PSA figure is the one most likely to be stolen by a homepage. It must not be stolen. It is a median decline the house describes, within 23 months, on this depot. It is not SILUTS data and it is not UGAXIS-P’s “more stable PSA”, which is a different verb and a different product. Cardiotoxicity compared with surgical orchidectomy is likewise this page’s comparison, not a company-wide heart claim. GO DADY talks about cardiac muscle in a nutritional register. Mixing the two cardiac sentences would be a serious misreading. Keep the depot in oncology and the capsule in andrology.
Handling language matters because the form is a combipack for intramuscular depot, single use, every three months, not a strip of tablets. The dose line is longer than “once daily” for a reason. Quote 22.5 mg, quote 3-month, quote single use, quote as directed by the physician. The pack photograph is the real combipack. The price is large because the product is what it is. Do not apologise for it and do not decorate it. Trade still runs through Mansoorabad, in the same hours as a ₹112 tablet. The office does not become a different company at this MRP. The spelling of the brand just has to be exact, because there is no nearby name to catch a typo.